Trupanion (TRUP) Tops Q2 EPS by 6c, Revenues Beat
Get Alerts TRUP Hot Sheet
Join SI Premium – FREE
Trupanion (NASDAQ: TRUP) reported Q2 EPS of $0.04, $0.06 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $117.9 million versus the consensus estimate of $114.58 million.
Second Quarter 2020 Financial and Business Highlights
- Total revenue was $117.9 million, an increase of 28% compared to the second quarter of 2019.
- Total enrolled pets (including pets from our other business segment) was 744,727 at June 30, 2020, an increase of 29% over the second quarter of 2019.
- Subscription business revenue was $92.5 million, an increase of 19% compared to the second quarter of 2019. On a constant currency basis, subscription business revenue increased 20% over the prior year period.
- Subscription enrolled pets was 529,400 at June 30, 2020, an increase of 15% over the second quarter of 2019.
- Net income was $1.4 million, or $0.04 per basic and diluted share, compared to a net loss of $(1.9) million, or $(0.06) per basic and diluted share, in the second quarter of 2019.
- Adjusted EBITDA was $5.5 million, compared to adjusted EBITDA of $1.3 million in the second quarter of 2019.
- Operating cash flow was $4.9 million and free cash flow was $3.1 million in the second quarter of 2020. This compared to operating cash flow of $2.9 million and free cash flow of $2.0 million in the second quarter of 2019.
“Across key financial and operational metrics, it was a very strong quarter for Trupanion,” said Darryl Rawlings, Founder and CEO of Trupanion. “I’m particularly proud of our service levels we provided to our members, which contributed to records in monthly average retention and the number of pet owners adding pets or referring friends to Trupanion in the quarter.”
For earnings history and earnings-related data on Trupanion (TRUP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras CEO says investors misunderstood margin guidance
- Paychex beats fourth quarter EPS estimates, stock slides
- Kadima sues NRx Pharmaceuticals over failed acquisition deal
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share